Schizophrenia CME Outcomes: Interprofessional Microlearning That Moved Confidence and Intent

Schizophrenia care asks clinicians to hold several moving parts at once: positive, negative, and cognitive symptoms; adherence risk; metabolic and cardiovascular comorbidity; and elevated suicide risk. Even with newer antipsychotics on the market, teams still struggle to appraise agents across symptom domains, operationalize long-acting injectables (LAIs), and address cognitive impairment where traditional therapies fall short. That is the gap a modular schizophrenia CME series has to close if education is going to change what happens at the bedside.

Why Schizophrenia Care Still Challenges the Interprofessional Team

Schizophrenia remains one of the most complex neuropsychiatric disorders. Beyond core psychiatric symptoms, clinicians routinely manage depression, substance use disorders, cardiometabolic disease, and suicide risk in the same visit or care episode. Practice gaps persist across the multidisciplinary psychiatric team: psychiatrists, physician assistants, nurse practitioners, psychiatric and mental health nurses, and clinical pharmacists all need a shared, current frame for efficacy, safety, adherence, and cognition.

Second- and third-generation antipsychotics continue to evolve. LAI formulations can reduce therapeutic nonadherence, but only if clinicians know how to select and introduce them. Emerging agents aimed at cognitive deficits add another layer that many teams have not yet folded into routine shared decision-making.

What Does High-Impact Schizophrenia CME Look Like in Practice?

High-impact interprofessional education in schizophrenia is less about a single lecture and more about a curriculum architecture that fits clinical workflows. Schizophrenia Update: Navigating the Latest in Research and Treatment was designed as a multi-modal, accredited continuing medical education initiative built around four competencies:

• Efficacy and safety appraisal: current and novel oral antipsychotics across positive, negative, and cognitive domains

• LAI optimization: newer long-acting injectables and adherence

• Cognitive dysfunction: mechanisms and trial evidence for agents aimed at cognitive impairment

• Shared decision-making: evidence-based choices inside individualized care plans

The activity was jointly accredited (CME/AAPA/NCPD/CPE) so the full psychiatric care team could learn from the same source material and leave with credit that matches their role.

How the Series Was Built

Led by Christoph U. Correll, MD, the curriculum used a 4-module Clinical Insights Microlearning Series so clinicians could engage in short, focused segments rather than a single long sitting:

1. Module 1: Understanding the Evolving Treatment Landscape

2. Module 2: Advances in Long-Acting Injectables

3. Module 3: Emerging Treatments for Cognitive Symptoms

4. Module 4: Applying Advances to Patient-Centered Care

Active learning and multi-channel delivery reinforced the modules: gamified case explorations; dual video and podcast distribution through the Full Stack Medicine® Podcast; and Clinical Pearls released 4 weeks after the activity to support Moore Level 5 outcomes. The design goal was straightforward: meet clinicians where they already learn, then follow up when they are back in practice.

What the Series Reported

Activity window: February 18, 2025, through February 17, 2026.

• 18,413 total learners

• 1,365 completers for credit (N=1,359 evaluation participants)

• Learners included MD/DO, PA, RN, NP, and PharmD

• 85% reported increased confidence

• 84% reported intent to apply learning to improve patient outcomes

• Matching pre/post assessments showed validated knowledge gains

In plain terms: a schizophrenia CME microlearning design reached a large interprofessional audience, moved confidence and stated intent to change practice, and documented knowledge improvement with matched pre/post measures.

Why These Numbers Matter to Planners

CME planners, society education staff, and jointly provided activity leads get scored on reach, completion, confidence, and stated intent. Schizophrenia care still sits in an interprofessional gap. Psychiatrists, PAs, NPs, nurses, and pharmacists rarely share a common baseline or perspective on key treatment decisions in schizophrenia, from evaluating drug efficacy and safety to utilizing long-acting injectables, managing cognitive symptoms, and engaging in shared decision-making. A lecture built for one license type rarely shifts how the team works.

The practical constraint is building short, gap-tied modules, reinforcing them where clinicians already learn, and capturing knowledge, confidence, and intent, without the heavy administrative burden of becoming a fully accredited CME provider.

What This Means If You Jointly Provide

Specialty societies and education partners often already own the clinical voice and the learner relationship. What many still need is a pathway to outcomes-driven, jointly provided credit without building and maintaining a fully fledged accreditation office.

Joint providership can help societies keep content and brand while a jointly accredited partner manages compliance, so the same outcomes-minded design can carry CME/CE for physicians, advanced practice clinicians, nurses, and pharmacists. That split is how this series ran. The host kept content and brand. i3 Health Joint Providership Services owned accreditation compliance.

The schizophrenia series illustrates a repeatable pattern: clear practice gaps, modular microlearning, multi-channel reinforcement, and evaluation that captures confidence, intent, and knowledge change across the care team. More education examples sit on i3 Health.

The Nitty Gritty

Who is this case study for?

CME planners, society education staff, jointly provided activity leads, and accreditation professionals who need outcomes beyond attendance.

What outcomes did Schizophrenia Update report?

18,413 total learners; 1,365 completers for credit (N=1,359 evaluation participants); 85% increased confidence; 84% intent to apply learning; matching pre/post knowledge gains. Window: February 18, 2025, through February 17, 2026.

Why microlearning for accreditation planning?

Four short modules fit real schedules, support modular credit, and leave room for podcast, video, and delayed Clinical Pearls when you are aiming beyond Level 1 outcomes.

Who led the curriculum?

Christoph U. Correll, MD. Four modules: treatment landscape, LAIs, cognitive symptoms, patient-centered application.

How does a society keep its brand and still issue jointly provided credit?

Joint providership. Host keeps content and brand. Jointly accredited partner owns compliance. See i3 Health Joint Providership Services.